Change from inhibition to stimulation by levan of AKR lymphoma following serial transfers.
A progressive increase in malignancy following serial passages of AKR lymphoma is often accompanied by loss in sensitivity to the antitumor agent, levan. In further transfers, stimulation of tumor growth, instead of inhibition, is sometimes observed. It is proposed that the shift from inhibition to stimulation of tumor growth by the immunomodulator levan may be due to a change during tumor progression in the sensitivity of the tumor cells to the reported dual effect of macrophages, inhibitory or stimulatory, on tumor growth.